Announced details
Regenerative medicine; process development, quality testing and investigational drug manufacturing for drug discovery seeds; support for regulatory approval; cell-processed products and regenerative medicine products
The center aims to shorten the time required from the arrival of cellular raw materials to the transportation and delivery of products by leveraging its location near Haneda Airport.
セルリソーシズ株式会社 is our subsidiary. The アルフレッサ Group has expertise in the development, transportation and delivery of regenerative medicine products and other products.
4th and 5th floors, Zone K, Haneda Innovation City, 1-1-4 Haneda Airport, Ota-ku, Tokyo
The impact of this matter on results for the current fiscal year is expected to be minor. Over the medium to long term, it is expected to contribute to an increase in corporate value.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Haneda Process Development Center (Haneda PDC), CDMO services, Total Supply Chain Service for Regenerative Medicine (TSCS) |
| Relationship with the Company | セルリソーシズ株式会社 is our subsidiary. The アルフレッサ Group has expertise in the development, transportation and delivery of regenerative medicine products and other products. |
| Launch date | Haneda PDC: 3 August 2026 (operations commenced; actual) / CDMO services: during fiscal 2026 (scheduled to begin) |
| Applicable area | Regenerative medicine; process development, quality testing and investigational drug manufacturing for drug discovery seeds; support for regulatory approval; cell-processed products and regenerative medicine products |
| Location | 4th and 5th floors, Zone K, Haneda Innovation City, 1-1-4 Haneda Airport, Ota-ku, Tokyo |
| Location scale | Total area: 1,018 m² |
| Quantitative Effects | The center aims to shorten the time required from the arrival of cellular raw materials to the transportation and delivery of products by leveraging its location near Haneda Airport. |
| Impact on Business Performance | The impact of this matter on results for the current fiscal year is expected to be minor. Over the medium to long term, it is expected to contribute to an increase in corporate value. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen development and manufacturing capabilities for a total supply chain service for regenerative medicine by providing early-stage support for establishing the manufacturing processes, conducting quality assessments and addressing regulatory requirements needed to commercialize drug discovery seeds.